CervoMed Inc. (CRVO)
- Previous Close
24.66 - Open
24.48 - Bid 23.46 x 100
- Ask 25.35 x 100
- Day's Range
24.05 - 24.91 - 52 Week Range
3.00 - 26.38 - Volume
18,970 - Avg. Volume
32,085 - Market Cap (intraday)
201.804M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.82 - Earnings Date May 14, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.50
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
www.cervomed.comRecent News: CRVO
Performance Overview: CRVO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRVO
Valuation Measures
Market Cap
199.49M
Enterprise Value
191.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
27.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-30.40%
Return on Assets (ttm)
-62.04%
Return on Equity (ttm)
--
Revenue (ttm)
7.14M
Net Income Avi to Common (ttm)
-2.17M
Diluted EPS (ttm)
-0.82
Balance Sheet and Cash Flow
Total Cash (mrq)
7.79M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.23M
Research Analysis: CRVO
Company Insights: CRVO
CRVO does not have Company Insights